3 Stocks That May Be Priced Below Their Estimated Value In August 2026
The United States market has recently experienced a 2.4% climb over the past week and a notable 20% increase over the last year, with earnings projected to grow by 17% annually in the coming years. In such an environment, identifying stocks that are potentially priced below their estimated value can be crucial for investors aiming to capitalize on future growth opportunities.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Western Digital (WDC) | $527.22 | $1017.67 | 48.2% |
| Upstart Holdings (UPST) | $29.43 | $56.76 | 48.2% |
| Palantir Technologies (PLTR) | $125.65 | $241.37 | 47.9% |
| Omada Health (OMDA) | $20.51 | $40.88 | 49.8% |
| Natera (NTRA) | $270.36 | $539.73 | 49.9% |
| Klaviyo (KVYO) | $18.10 | $34.70 | 47.8% |
| Hims & Hers Health (HIMS) | $30.82 | $61.59 | 50% |
| HBT Financial (HBT) | $35.79 | $69.21 | 48.3% |
| FormFactor (FORM) | $108.80 | $208.51 | 47.8% |
| Commvault Systems (CVLT) | $124.93 | $249.54 | 49.9% |
Let's explore several standout options from the results in the screener.
FormFactor (FORM)
Overview: FormFactor, Inc. designs, manufactures, and sells probe cards and related testing equipment globally, with a market cap of approximately $8.48 billion.
Operations: The company's revenue segments include the design, manufacture, and sale of probe cards, analytical probes, probe stations, thermal systems, cryogenic systems, and related services across various international markets.
Estimated Discount To Fair Value: 47.8%
FormFactor's recent earnings report shows strong financial performance, with second-quarter net income rising significantly to US$56.21 million from US$9.09 million a year ago. Despite being highly volatile and experiencing substantial insider selling, the stock trades at 47.8% below its estimated fair value of US$208.51 based on discounted cash flow analysis. The company's strategic expansion in Taiwan and projected earnings growth of 43.7% annually position it as an undervalued opportunity in the semiconductor sector.
- The analysis detailed in our FormFactor growth report hints at robust future financial performance.
- Click here and access our complete balance sheet health report to understand the dynamics of FormFactor.
Natera (NTRA)
Overview: Natera, Inc. is a diagnostics company that develops and commercializes molecular testing services globally, with a market cap of approximately $38.72 billion.
Operations: The company generates revenue of approximately $2.50 billion from its molecular testing services developed and commercialized worldwide.
Estimated Discount To Fair Value: 49.9%
Natera's stock is trading at 49.9% below its estimated fair value of US$539.73, suggesting significant undervaluation based on discounted cash flow analysis. The company is expected to achieve profitability within three years and has a forecasted annual earnings growth rate of 59.38%. Recent strategic partnerships, such as those with Aveta Biomics and Eledon Pharmaceuticals, bolster its position in transplant diagnostics and oncology, potentially enhancing future revenue streams despite slower projected revenue growth relative to some competitors.
- Upon reviewing our latest growth report, Natera's projected financial performance appears quite optimistic.
- Get an in-depth perspective on Natera's balance sheet by reading our health report here.
Everpure (P)
Overview: Everpure, Inc. offers data storage and management technologies, products, and services both in the United States and internationally with a market cap of $26.64 billion.
Operations: The company generates revenue from its Computer Storage Devices segment, amounting to $3.94 billion.
Estimated Discount To Fair Value: 40.7%
Everpure is trading at 40.7% below its estimated fair value of US$135.17, highlighting potential undervaluation based on cash flow analysis. The company's earnings are forecasted to grow significantly at 28.37% annually over the next three years, outpacing the broader US market's growth rate. Despite being dropped from several Russell indices, Everpure's strategic alliances and product innovations in AI and data management strengthen its operational capabilities and future revenue prospects amidst insider selling concerns.
- According our earnings growth report, there's an indication that Everpure might be ready to expand.
- Delve into the full analysis health report here for a deeper understanding of Everpure.
Seize The Opportunity
- Reveal the 148 hidden gems among our Undervalued US Stocks Based On Cash Flows screener with a single click here.
- Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com